COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

Key facts

Sponsor

Edwards Lifesciences

Principal Investigator

D. Scott Lim, MD

University of Virginia Medical Center

Intervention

SAPIEN 3/SAPIEN 3 Ultra RESILIA THV(device)

Enrollment

108 enrolled

Eligibility

All sexes

Timeline

2016 – 2031

Study locations (25)

• Arkansas Children's Hospital, Little Rock, Arkansas, United States
• University of California, Los Angeles, Los Angeles, California, United States
• University of California,, San Francisco (UCSF), San Francisco, California, United States
• Childrens Hospital of Colorado, Aurora, Colorado, United States
• Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia, United States
• University of Kentucky, Lexington, Kentucky, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Boston Children's Hospital, Boston, Massachusetts, United States
• Mayo Clinic Rochester, Rochester, Minnesota, United States
• St. Louis Children's Hospital, St Louis, Missouri, United States
• Washington University Barnes- Jewish Medical/ St. Louis Children's Hospital, St Louis, Missouri, United States
• Columbia University Medical Center/NYPH, New York, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• The Lindner Research Center at Christ Hospital, Cincinnati, Ohio, United States
• Cincinnati Children's Hospital, Cincinnati, Ohio, United States
• +10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Visceral heterotaxy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT04860765
  COMPASSION S3 Post-Approval Study
  Edwards Lifesciences

See all trials for Visceral heterotaxy →